Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders [Financial Post (Toronto, Ontario, ...
XORTX Therapeutics Inc. (XRTX)
Company Research
Source: Financial Post
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024. Leading independent third party proxy advisory firm ISS has recommended that shareholders vote FOR all the proposed resolutions. The Board of Directors of XORTX recommends that Shareholders vote FOR ALL proposed items Your vote is important no matter how many shares you hold. Please vote today. The proxy voting deadline is 10:00 am (Calgary time) on Tuesday, September 10, 2024 Meeting Details XORTX will hold
Show less
Read more
Impact Snapshot
Event Time:
XRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XRTX alerts
High impacting XORTX Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
XRTX
News
- XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024GlobeNewswire
- XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswire
- XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement [Financial Post (Toronto, Ontario, Canada)]Financial Post
- XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswire
XRTX
Sec Filings
- 11/22/24 - Form 424B3
- 11/22/24 - Form 424B3
- 11/15/24 - Form F-1
- XRTX's page on the SEC website